HK inno.N kickstarts IPO process Valuation likely to be around $1.78 bln
Translated by Kim So-in 공개 2021-05-10 08:27:31
이 기사는 2021년 05월 10일 08:05 thebell 에 표출된 기사입니다.
South Korea’s drug maker HK inno.N plans to go public on the secondary Kosdaq market in the third quarter, with its valuation likely to be around 2 trillion won ($1.78 billion). The firm’s largest shareholder Kolmar Korea valued the company at around 1.24 trillion won at the end of last month.HK inno.N submitted its preliminary application for initial public offering (IPO) on Tuesday, about one-and-a-half years after it hired Korea Investment & Securities, Samsung Securities and JP Morgan as its bookrunners at the end of 2019.
The review process normally takes 45 working days. It is likely to make its stock market debut in the third quarter considering its follow-up procedures.
The company will sell more than 10 million shares including 5.78 million new shares and 4.34 million shares held by existing shareholders.
Financial investors including H&Q Korea, Mirae Asset Private Equity, STIC Investments are expected to sell their shares in the planned IPO. Funds managed by the financial investors own a combined 47.3% stake in the drug maker.
The financial investors invested around 350 billion won when Kolmar Korea acquired HK inno.N from CJ CheilJedang in April 2018 under the condition of HK inno.N’s IPO by 2022.
The three financial investors completed preparations for their exits last month, converting all their redeemable convertible preference shares into common shares. Industry watchers expect the investors to maximize their returns by selling a portion of their stake first and then selling the rest in the market depending on the stock price movement.
HK inno.N, formerly CJ Healthcare, produces pharmaceuticals and health functional foods. The company generates an annual revenue of around 500 billion won, with an operating margin of 10~15%. It recorded revenue of 598.4 billion won, operating income of 87 billion won and net income of 27.9 billion won in 2020, its best financial performance ever.
Kolmar Korea invested 50 billion won in HK inno.N’s rights offering in the form of third party placement on April 22. The largest shareholder bought 934,579 common shares issued by HK inno.N at 53,500 per share. Based on the price, the valuation of the drug maker is around 1.24 trillion won.
Market insiders expect the company to set its valuation as much as 2 trillion won for its planned IPO, because it recently posted the best performance despite the Covid-19 pandemic and stock prices of its peer companies including Dong-A Socio Holdings, Kwangdong Pharmaceutical and Handok are on the rise.
Kolmar Korea and the financial investors injected total 1.3 trillion won to acquire HK inno.N three years ago. (Reporting by Cheol Kang)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [아시아나 화물사업부 M&A]MBK 손잡은 에어프레미아, 다크호스 등극
- [대기업 프로스포츠 전술전략]전북현대, '돈방석' 기회 끝내 놓쳤다
- 골프존, 주가 하락에 발목잡혔나…GDR 분할 '무산'
- [Art Price Index]시장가치 못 찾은 퍼포먼스 작품
- 하이브 '집안싸움'이 가리키는 것
- 이익률 업계 톱인데 저평가 여전…소통 강화하는 OCI
- KB금융, 리딩금융의 품격 ‘주주환원’ 새 패러다임 제시
- 대외 첫 메시지 낸 최창원 의장의 속내는
- KG모빌리티, 라인 하나로 전기차까지
- [이사회 분석]갈 길 바쁜 LS이브이코리아, 사외이사 없이 간다